Gilead Sciences' (GILD, $74.10) developing treatment for Coronavirus is already in use in US
Gilead Sciences’ experiment with coronavirus treatment is already being used in the US.
The Centers for Disease Control director Robert Redfield told lawmakers on a House appropriations panel Tuesday that remdesivir, the coronavirus treatment that Gilead is developing, was being used on compassionate grounds in Washington state.
Federal Food & Drug Administration regulations allow the use of unapproved drugs in critical situations when there are very limited alternatives for treating a disease.
Gilead’s treatment for Cornavirus was first designed to fight the Ebola virus.
Gilead is expecting results from trials as early as next month. It has said that it would increase supplies as early as possible in the near term.
GILD's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for GILD turned positive on July 01, 2025. Looking at past instances where GILD's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 30, 2025. You may want to consider a long position or call options on GILD as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in of 323 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 270 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
GILD broke above its upper Bollinger Band on June 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.976) is normal, around the industry mean (5.632). P/E Ratio (16.196) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.451) is also within normal values, averaging (3.004). Dividend Yield (0.041) settles around the average of (0.161) among similar stocks. P/S Ratio (3.381) is also within normal values, averaging (3.643).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutic products and treatments for life threatening diseases
Industry PharmaceuticalsMajor
Advertisement